Table 5.
Tertiles | No. of Patients | Recurrence | Overall Death | Death from Breast Cancer | ||||||
---|---|---|---|---|---|---|---|---|---|---|
No. of Events | HR (95% CI) | Ptrend | No. of Events | HR (95% CI) | Ptrend | No. of Events | HR (95% CI) | Ptrend | ||
Unadjusted Model | ||||||||||
Tertiles 1 | 409 | 61 | 1 [Reference] | 0.41 | 31 | 1 [Reference] | 0.59 | 28 | 1 [Reference] | 0.66 |
Tertiles 2 | 409 | 49 | 0.80 (0.54–1.19) | 32 | 0.99 (0.60–1.63) | 29 | 0.99 (0.59–1.68) | |||
Tertiles 3 | 408 | 55 | 0.85 (0.58–1.26) | 35 | 1.14 (0.70–1.85) | 31 | 1.12 (0.67–1.87) | |||
Model 1 | ||||||||||
Tertiles 1 | 409 | 61 | 1 [Reference] | 0.50 | 31 | 1 [Reference] | 0.46 | 28 | 1 [Reference] | 0.67 |
Tertiles 2 | 409 | 49 | 0.80 (0.54–1.19) | 32 | 1.03 (0.62–1.72) | 29 | 0.96 (0.57–1.63) | |||
Tertiles 3 | 408 | 55 | 0.88 (0.59–1.30) | 35 | 1.20 (0.74–1.96) | 31 | 1.12 (0.67–1.88) | |||
Model 2 | ||||||||||
Tertiles 1 | 409 | 61 | 1 [Reference] | 0.99 | 31 | 1 [Reference] | 0.20 | 28 | 1 [Reference] | 0.30 |
Tertiles 2 | 409 | 49 | 0.86 (0.57–1.30) | 32 | 1.15 (0.68–1.93) | 29 | 1.07 (0.62–1.86) | |||
Tertiles 3 | 408 | 55 | 1.01 (0.64–1.59) | 35 | 1.45 (0.82–2.56) | 31 | 1.37 (0.76–2.49) |
Notes: Cox proportional hazards models were used to investigate association of tertiles of dietary patterns and time to outcome. Model 1 were adjusted by age at 18-month follow-up (continuous), stage at diagnosis, ER status, PR status, HER2 status, histology, chemotherapy, radiotherapy and adjuvant hormonal therapy usage at 18-month follow-up. Model 2 were adjusted by age at 18-month follow-up (continuous), total number of comorbidities at 18-month follow-up, stage at diagnosis, ER status, PR status, HER2 status, histology, chemotherapy, radiotherapy, adjuvant hormonal therapy usage at 18-month follow-up, menopausal status at 18-month follow-up, BMI at 18-month follow-up (continuous), level of physical activity at 18-month follow-up (continuous) and total energy intake at 18-month follow-up (continuous).
Abbreviations: HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER 2, human epidermal-growth-factor receptor 2; BMI, body mass index.